These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22801851)

  • 1. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.
    Patel RD; Blair MP; Shapiro MJ; Lichtenstein SJ
    Arch Ophthalmol; 2012 Jun; 130(6):801-2. PubMed ID: 22801851
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
    Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
    J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of retinopathy of prematurity after bevacizumab injection.
    Hu J; Blair MP; Shapiro MJ; Lichtenstein SJ; Galasso JM; Kapur R
    Arch Ophthalmol; 2012 Aug; 130(8):1000-6. PubMed ID: 22491394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity.
    Ehmann D; Greve M
    Can J Ophthalmol; 2014 Apr; 49(2):228-31. PubMed ID: 24767234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?
    Spandau U
    Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
    Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P
    Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118
    [No Abstract]   [Full Text] [Related]  

  • 7. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
    Kychenthal A; Dorta P
    Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.
    Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D
    Retina; 2011; 31(7):1239-47. PubMed ID: 21555969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
    Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
    J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
    Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA
    J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
    Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
    JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
    [No Abstract]   [Full Text] [Related]  

  • 12. Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment.
    Hoang QV; Kiernan DF; Chau FY; Shapiro MJ; Blair MP
    Arch Ophthalmol; 2010 Aug; 128(8):1080-1. PubMed ID: 20697016
    [No Abstract]   [Full Text] [Related]  

  • 13. Retinopathy of Prematurity: Intravitreal injections of bevacizumab: timing, technique, and outcomes.
    Mintz-Hittner HA
    J AAPOS; 2016 Dec; 20(6):478-480. PubMed ID: 27816750
    [No Abstract]   [Full Text] [Related]  

  • 14. Off-label use of bevacizumab in retinopathy of prematurity.
    Rishi E; Rishi P; Ratra D; Bhende M
    Retina; 2009 Feb; 29(2):284; author reply 284-5. PubMed ID: 18854784
    [No Abstract]   [Full Text] [Related]  

  • 15. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
    Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
    Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
    Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
    Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity.
    Jang SY; Choi KS; Lee SJ
    J AAPOS; 2010 Oct; 14(5):457-9. PubMed ID: 21035077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.